COMPANY PROFILE / #735
BigHat Biosciences
Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.Privately Held (backing)
已融资99
最新估值—
员工数—
成立年份Phenomic AI, Revr, Deep Genomics, Manifold Bio, ProteinQure, LabGenius Therapeutics, OneThree Biotech, Xaira Therapeutics, Integrated DNA Technologies, Relay Therapeutics, Molecule.one, Valo, BenchSci, Genesis Molecular AI, Numerate, Xilis, InterAx, Nabla Bio, Gen9, NuMedii, Generate Biomedicines, Exscientia, Verge Analytics, X-37, BioTheryx, Nurix Therapeutics, C4 Therapeutics, Peptone, PathAI, Quark Pharmaceuticals, insitro, Theraclone Sciences, AbCellera Biologics, Berg, Owkin, Ingenza, Numerion Labs, BenevolentAI
公司概况
- Companies
- BigHat Biosciences
- Description
- —
- Website
- San Mateo, CA
- HQ Location
- Developer of an experimental antibody platform designed to empower biological antibodies and other therapeutic proteins. The company's platform is agile, multi-objective, and data-driven and integrates a wet laboratory with artificial intelligence and machine learning techniques to design antibodies, enabling drug developers to create antibodies and undertake novel biotherapeutic designs.
- Year Founded
- Phenomic AI, Revr, Deep Genomics, Manifold Bio, ProteinQure, LabGenius Therapeutics, OneThree Biotech, Xaira Therapeutics, Integrated DNA Technologies, Relay Therapeutics, Molecule.one, Valo, BenchSci, Genesis Molecular AI, Numerate, Xilis, InterAx, Nabla Bio, Gen9, NuMedii, Generate Biomedicines, Exscientia, Verge Analytics, X-37, BioTheryx, Nurix Therapeutics, C4 Therapeutics, Peptone, PathAI, Quark Pharmaceuticals, insitro, Theraclone Sciences, AbCellera Biologics, Berg, Owkin, Ingenza, Numerion Labs, BenevolentAI
- Keywords
- 2025: 99, 2024: 109, 2023: 50, 2022: 37, 2021: 22, 2020: 8
- Competitors
- —
- Ownership Status
- —
- Company Financing Status
- Privately Held (backing)
融资与估值
- Total Raised
- 99
- First Financing Date
- 20.00
- First Financing Size
- —
- First Financing Valuation
- peyton@bighatbio.com
- Last Financing Date
- —
- Last Financing Deal Type
- —
- Last Financing Size
- Secondary Transaction - Private
- Last Financing Valuation
- —
- Last Financing Status
- —
- Last Known Valuation
- —
- Last Known Valuation Date
- Later Stage VC
- Last Known Valuation Deal Type
- 5.30
- Valuation Estimate
- 17-Apr-2025
- Valuation Estimate Growth Rate
- antibodies developer, biobetters developer, biopharmaceutical innovation, bispecific platform, protein therapeutics, therapeutic protein, therapeutic protein drugs
- Active Investors
- Venture Capital-Backed
- # Active Investors
- 14%
- Acquirers
- 8VC, Amar Hussain, AME Cloud Ventures, Amgen, Amgen Ventures, Andreessen Horowitz, Axial (San Francisco), BOLD Longevity Growth, Bristol-Myers Squibb, Catalio Capital Management, Gaingels, GRIDS Capital, Innovation Endeavors Management Company, Intermountain Ventures, Jonathan Golden, Kevin Moore, Lilly USA, MBC BioLabs, MSD Global Health Innovation Fund, National Institute of Standards and Technology, Olima Ventures, Quadrille Capital, Quain Investments, S32, Samsung Venture Investment, U.S. Department of Commerce, Zain S Hasan Charitable Remainder Trust
团队与联系人
- Employees
- —
- Employee Growth %
- 2019
- Employee History
- —
- Primary Contact
- 148.30
- Primary Contact Title
- +1 (650) 394-7679
- Primary Contact Email
- Peyton Greenside
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- 100.56%
- Growth Rate
- —
- Growth Rate % Change
- —
- Growth Rate Percentile
- —
- Size Multiple
- —
- Size Multiple % Change
- 332.00
- Size Multiple Change
- —
- Size Multiple Percentile
- —
- Majestic Referring Domains
- —
- SimilarWeb Unique Visitors
- —
- SimilarWeb Unique Visitors Change
- 22-Oct-2019
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 33%
- Success Probability Over Time – 3 Year
- 42%
- Success Probability Over Time – 5 Year
- Co-Founder, Chief Executive Officer, Chief Scientific Officer, President & Board Member
记录来源：public.companies · 原始序号 #735 · 所有字段均按数据库原值展示。